Int J Angiol
DOI: 10.1055/s-0034-1384822
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

New Impella Cardiac Power Device Used in Patient with Cardiogenic Shock due to Nonischemic Cardiomyopathy

Marek Cena
1   Division of Cardiology, University of Texas Medical Branch, Galveston, TX
Frances Karam
2   Division of Anesthesiology, Baylor College of Medicine, Houston, TX
Rajesh Ramineni
1   Division of Cardiology, University of Texas Medical Branch, Galveston, TX
Wissam Khalife
1   Division of Cardiology, University of Texas Medical Branch, Galveston, TX
Alejandro Barbagelata
1   Division of Cardiology, University of Texas Medical Branch, Galveston, TX
› Author Affiliations
Further Information

Publication History

Publication Date:
02 December 2014 (online)


The new percutaneous Impella CP (Cardiac Power; Abiomed, Inc., Danvers, MA) was designed to provide a higher level of support than Impella 2.5 (Abiomed, Inc.). We present the first documented case of a patient that was transitioned from the Impella 2.5 to Impella CP. A 48-year-old male patient with no medical history was transferred to our institution with a one day history of worsening shortness of breath. The patient was unstable and found to have monomorphic ventricular tachycardia at 220 beats/min that was cardioverted to normal sinus rhythm. An emergent right and left heart catheterization was performed showing nonobstructive coronary artery disease, biventricular failure with a left ventricular ejection fraction (LVEF) of 5 to 10%, high pulmonary capillary wedge pressure (PCWP) 22 mm Hg, right atrial (RA) pressure 22 mm Hg, and a very low cardiac index of 1.0 L/min/m2. Because of severe cardiogenic shock, Impella 2.5 was inserted providing flow up to 2.1 L/min; however, the patient remained unstable and critically ill with severe multiorgan failure. To provide better mechanical support, the device was upgraded to the new Impella CP that can provide up to 3.5 L/min of cardiac output. Over the course of the next 72 hours, the patient showed significant improvement in hemodynamics and cardiac function (LVEF 45%), with recovery of liver function. The Impella CP was removed with no complications. The new Impella CP was shown to be safe and effective for prolonged use in critically ill patients and may significantly improve their prognosis.

  • References

  • 1 Thiele H, Zeymer U, Neumann FJ , et al; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367 (14) 1287-1296
  • 2 Dixon SR, Henriques JPS, Mauri L , et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. JACC Cardiovasc Interv 2009; 2 (2) 91-96
  • 3 O'Neill WW, Kleiman NS, Moses J , et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation 2012; 126 (14) 1717-1727
  • 4 Griffith BP, Anderson MB, Samuels LE, Pae Jr WE, Naka Y, Frazier OH. The RECOVER I: a multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. J Thorac Cardiovasc Surg 2013; 145 (2) 548-554
  • 5 Seyfarth M, Sibbing D, Bauer I , et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008; 52 (19) 1584-1588